Breaking News

Glenmark Launches Antiviral COVID-19 Treatment in India

Becomes first pharma company in India to receive regulatory approval for oral antiviral Favipiravir, for the treatment of mild to moderate COVID-19.

By: Contract Pharma

Contract Pharma Staff

In a landmark development for COVID-19 patients in India, Glenmark Pharmaceuticals, a research-led, integrated global pharmaceutical company, has launched antiviral drug Favipiravir (brand name FabiFlu) for the treatment of mild to moderate COVID-19 patients. Glenmark has received manufacturing and marketing approval from India’s drug regulator, making FabiFlu the first oral Favipiravir-approved medication in India for the treatment of COVID-19.   Favipiravir is backed by strong clinical e...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters